Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Investigation for the presence of antierythropoietin antibodies in patients with myelodysplastic syndromes
Autore:
Voulgari, PV; Hatzimichael, EC; Tsiara, S; Tzallas, C; Drosos, AA; Bourantas, KL;
Indirizzi:
Univ Ioannina, Sch Med, Dept Internal Med, Rheumatol Clin, GR-45110 Ioannina, Greece Univ Ioannina Ioannina Greece GR-45110 l Clin, GR-45110 Ioannina, Greece Univ Ioannina, Sch Med, Dept Internal Med, Haematol Clin, GR-45110 Ioannina, Greece Univ Ioannina Ioannina Greece GR-45110 l Clin, GR-45110 Ioannina, Greece Univ Ioannina, Sch Med, Biol Chem Lab, GR-45110 Ioannina, Greece Univ Ioannina Ioannina Greece GR-45110 em Lab, GR-45110 Ioannina, Greece
Titolo Testata:
EUROPEAN JOURNAL OF HAEMATOLOGY
fascicolo: 1, volume: 66, anno: 2001,
pagine: 31 - 36
SICI:
0902-4441(200101)66:1<31:IFTPOA>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-NECROSIS-FACTOR; RECOMBINANT-HUMAN-ERYTHROPOIETIN; COLONY-STIMULATING FACTOR; RED-CELL APLASIA; SYSTEMIC-LUPUS-ERYTHEMATOSUS; FACTOR-ALPHA; IMMUNOLOGICAL ABNORMALITIES; MARROW-CELLS; SERUM LEVELS; BONE-MARROW;
Keywords:
myelodysplastic syndromes; anti-epo autoantibodies; anemia; rHuEpo; response;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
45
Recensione:
Indirizzi per estratti:
Indirizzo: Bourantas, KL POB 37, Ioannina 45002, Greece POB 37 Ioannina Greece 45002 OB 37, Ioannina 45002, Greece
Citazione:
P.V. Voulgari et al., "Investigation for the presence of antierythropoietin antibodies in patients with myelodysplastic syndromes", EUR J HAEMA, 66(1), 2001, pp. 31-36

Abstract

Objectives: Recombinant human erythropoietin (rHuEpo) improves anemia in 25% of patients with myelodysplastic syndromes (MDS). The variable and sometimes low response rate to rHuEpo treatment raises the question whether the existence of autoantibodies against erythropoietin (L-po) is partially responsible. In the present study we investigated the presence of anti-epo autoantibodies in MDS patients. Methods: Forty-three patients with MDS were studied. Sixteen patients had refractory anemia (RA), 13 had RA with ringed sideroblasts, 3 had RA with excess of blasts (RAEB), 9 had RAEB in transformation and 2 patients had chronic myelomonocytic leukemia. They were divided in 3 groups according to rHuEpo treatment. Group A consisted of 10 patientswho did not receive rHuEpo treatment. Group B included 13 patients who were on rHuEpo treatment (150 IU/kg subcutaneously, 3 times weekly) showing anincrease of hemoglobin (Hb) values or reduction of transfusion requirements and Group C consisted of 20 patients who did not respond or stopped responding to rHuEpo treatment. Laboratory studies consisted of a complete bloodcell count, measurement of serum epo and determination of anti-epo antibodies using ELISA. Results: There were no significant differences with regardto age and sex among the three groups. No autoantibodies against epo were found in the examined sera, apart from a female patient from group A who showed a low positive titer. Conclusion: We suggest that anti-epo autoantibodies do not contribute to the development of MDS-related anemia and al-e notresponsible for the modest response to rHuEpo treatment, Further investigation is needed to identify possible reasons for the low response rate to rHuEpo treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/09/20 alle ore 06:27:02